Recent Updates
Recently added Catalysts

Loteprednol etabonate base

Phase 2

Allergic Conjunctivitis | Small molecule | Other |Bausch + Lomb Corporation|Last Updated: Mar 21, 2012

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindPLACEBO_CONTROLLEDBiomarker
Total Trials1
Total Enrollment101
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT01107405Loteprednol Ophthalmic Base Compared to Loteprednol Ophthalmic Suspension vs Placebo in an Allergen ChallengePHASE2 COMPLETED 101Apr 1, 2010Aug 1, 2010Mar 21, 20121 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Ocular Itching
Visit 4 (8 hr re-challenge)

Evaluated by subject at 3, 5, and 7 min post challenge on a scale of 0-4 where 0=no itching and 4=incapacitating itch.

Conjunctival Redness
Visit 4 (8 hr re-challenge)

Evaluated by investigator at 7, 15 and 20 minutes post challenge on a scale of 0-4 where 0= no redness and 4=extremely severe redness.

Secondary Endpoints
Ocular Itching
Visit 3 (initial challenge)
Conjunctival Redness
Visit 3 (initial challenge)
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Loteprednol etabonate base (QD)ACTIVE_COMPARATORLoteprednol etabonate ophthalmic base dosed once/day.
Loteprednol etabonate base (BID)ACTIVE_COMPARATORLoteprednol etabonate ophthalmic base dosed two times/day
Loteprednol etabonate base (QID)ACTIVE_COMPARATORLoteprednol etabonate ophthalmic base dosed four times/day.
Loteprednol etabonate suspension (QID)ACTIVE_COMPARATORLoteprednol etabonate ophthalmic suspension dosed four times/day
Vehicle of loteprednol etabonatePLACEBO_COMPARATORVehicle of loteprednol etabonate, dosed either QD, BID, or QID
Interventions
NameTypeDescription
Loteprednol etabonate base (QD)DRUGLoteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
Loteprednol etabonate base (BID)DRUGLoteprednol etabonate ophthalmic base BID dosing for 2 weeks
Loteprednol etabonate base (QID)DRUGLoteprednol Etabonate ophthalmic base four times/day dosing for 2 week
Loteprednol etabonate suspensionDRUGLoteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
Vehicle of loteprednol etabonateDRUGVehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
Unlock Study Design Details
Eligibility Criteria
Age Range10 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Positive history of ocular allergies and positive skin test reaction to cat hair, cat dander, grasses, ragweed, and/or trees within the past 24 months. * Calculated best-corrected visual acuity of 0.70 logMAR or better in each eye as measured using the ETDRS chart. * Positive ...

Countries:United States
Unlock Eligibility Criteria